Phase I study of dose-dense chemotherapy (DDC) alternating cisplatin (CDDP), topotecan (TPT), and paclitaxel (PTX) with CDDP, amrubicin (AMR), and PTX under granulocyte colony-stimulating factor support for extensive-stage small-cell lung cancer (ES-SCLC).

Junta Tanaka,Satoshi Watanabe,Hiroshi Kagamu,Daisuke Ishikawa,Koichiro Nozaki,Tomohiro Tanaka,Masaaki Okajima,Satoru Miura,Ichiei Narita,Hirohisa Yoshizawa

Phase I study of dose-dense chemotherapy (DDC) alternating cisplatin (CDDP), topotecan (TPT), and paclitaxel (PTX) with CDDP, amrubicin (AMR), and PTX under granulocyte colony-stimulating factor support for extensive-stage small-cell lung cancer (ES-SCLC).

2014

Junta Tanaka
Satoshi Watanabe
Hiroshi Kagamu
Daisuke Ishikawa
Koichiro Nozaki
Tomohiro Tanaka
Masaaki Okajima
Satoru Miura
Ichiei Narita
Hirohisa Yoshizawa

e18553 Background: Platinum-based combination is the mainstay of chemotherapy for ES-SCLC, with limited recent fruit of new agent development. In terms of treatment modality, dose-intensive chemoth...

Keywords:

Extensive-stage small cell lung cancer
Pathology
Granulocyte colony-stimulating factor
Dose-dense chemotherapy
Amrubicin
Topotecan
Cisplatin
Cancer research
Paclitaxel
Medicine
Chemotherapy
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations